AU2023240513A1 - Pyrazine amide derivatives - Google Patents

Pyrazine amide derivatives Download PDF

Info

Publication number
AU2023240513A1
AU2023240513A1 AU2023240513A AU2023240513A AU2023240513A1 AU 2023240513 A1 AU2023240513 A1 AU 2023240513A1 AU 2023240513 A AU2023240513 A AU 2023240513A AU 2023240513 A AU2023240513 A AU 2023240513A AU 2023240513 A1 AU2023240513 A1 AU 2023240513A1
Authority
AU
Australia
Prior art keywords
carboxamide
pyrazine
indol
amino
methylpropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023240513A
Other languages
English (en)
Inventor
Richard Yichong Huang
Thomas Martin Kirrane Jr.
Vanessa Marx
Anne-Catherine MATA
Christopher Ronald Sarko
Benjamin Robert TAFT
Fumiaki Yokokawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2023240513A1 publication Critical patent/AU2023240513A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fuel Cell (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023240513A 2022-03-24 2023-03-22 Pyrazine amide derivatives Pending AU2023240513A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263269879P 2022-03-24 2022-03-24
US63/269,879 2022-03-24
PCT/IB2023/052827 WO2023180964A1 (en) 2022-03-24 2023-03-22 Pyrazine amide derivatives

Publications (1)

Publication Number Publication Date
AU2023240513A1 true AU2023240513A1 (en) 2024-07-18

Family

ID=85979464

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023240513A Pending AU2023240513A1 (en) 2022-03-24 2023-03-22 Pyrazine amide derivatives

Country Status (10)

Country Link
US (1) US20250197376A1 (https=)
EP (1) EP4499631A1 (https=)
JP (1) JP2025509917A (https=)
CN (1) CN118591538A (https=)
AU (1) AU2023240513A1 (https=)
CA (2) CA3181279A1 (https=)
CO (1) CO2024010469A2 (https=)
DO (1) DOP2024000149A (https=)
WO (1) WO2023180964A1 (https=)
ZA (1) ZA202405048B (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009137081A2 (en) * 2008-05-07 2009-11-12 Massachusetts Institute Of Technology Small molecule inhibitors of plasmodium falciparum dihydroorotate dehydrogenase
CN102089278A (zh) * 2008-06-11 2011-06-08 Irm责任有限公司 用于治疗疟疾的化合物和组合物
ES2921576T3 (es) * 2008-12-19 2022-08-29 Vertex Pharma Compuestos útiles como inhibidores de la quinasa ATR
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
LT2925757T (lt) * 2012-11-19 2017-12-27 Novartis Ag Junginiai ir kompozicijos, skirti parazitinių ligų gydymui
WO2016089977A1 (en) * 2014-12-03 2016-06-09 Celgene Corporation Substituted indazole compounds, compositions thereof, and methods of treatment therewith
CN110023312A (zh) * 2016-10-13 2019-07-16 由卫生与公众服务部部长代表的美利坚合众国 阻止疟疾寄生虫传播的化合物和方法
WO2018081863A1 (en) * 2016-11-04 2018-05-11 University Of Wollongong 6-SUBSTITUTED DERIVATIVES OF HEXAMETHYLENE AMILORIDE AS INHIBITORS OF uPA AND USES THEREOF
EP3790878A1 (en) * 2018-05-11 2021-03-17 The United States of America, as represented by the Secretary, Department of Health and Human Services Quinoline compounds and their preparation and use as antimalarial agents

Also Published As

Publication number Publication date
WO2023180964A1 (en) 2023-09-28
ZA202405048B (en) 2025-09-25
EP4499631A1 (en) 2025-02-05
CA3181279A1 (en) 2023-09-24
CN118591538A (zh) 2024-09-03
JP2025509917A (ja) 2025-04-11
US20250197376A1 (en) 2025-06-19
CO2024010469A2 (es) 2024-08-08
CA3251003A1 (en) 2023-09-28
DOP2024000149A (es) 2024-08-30

Similar Documents

Publication Publication Date Title
EP3209651B9 (en) Carbazole derivatives
CA2932870C (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis
JP2020524148A (ja) 置換５−シアノインドール化合物及びその使用
KR102835904B1 (ko) N-치환된 테트라히드로티에노피리딘 유도체 및 이의 용도
JP2021513549A (ja) インドール−２、３−ジオキシゲナーゼ阻害剤としてのスピロ化合物
CN117355522A (zh) PKC-theta调节剂
CN103857670B (zh) 2-氧代-哌啶基衍生物
EP3810598A1 (en) Cyanotriazole compounds and uses thereof
CN110678468B (zh) 用于治疗寄生虫病的5,6-稠合双环化合物及其组合物
CN106986859B (zh) 吲哚衍生物及其用途
AU2023240513A1 (en) Pyrazine amide derivatives
AU2024289347A1 (en) Nmt inhibitor, and preparation method therefor and use thereof
JP7634532B2 (ja) 寄生虫病の処置のための化合物及び組成物
CN119998274A (zh) Ulk抑制剂
JP2024543107A (ja) 疾患又は障害の治療のためのナフチリジノン誘導体
WO2025163522A1 (en) Cyanotriazole compounds and uses thereof
KR20260054707A (ko) Cdk4 키나아제 억제제로 사용되는 화합물 및 이의 응용
HK40127025A (zh) Parp1抑制剂及其用途
HK40126682A (zh) 氮杂环丁烷和吡咯烷parp1抑制剂及其用途
HK1238642A1 (en) Carbazole derivatives
HK1238642B (en) Carbazole derivatives
HK1226725A1 (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis
HK1226725B (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis